WO2006032216A2 - Peptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas - Google Patents
Peptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas Download PDFInfo
- Publication number
- WO2006032216A2 WO2006032216A2 PCT/CU2005/000008 CU2005000008W WO2006032216A2 WO 2006032216 A2 WO2006032216 A2 WO 2006032216A2 CU 2005000008 W CU2005000008 W CU 2005000008W WO 2006032216 A2 WO2006032216 A2 WO 2006032216A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- peptides
- peptide
- cells
- patients
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 235
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 139
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 102000006303 Chaperonin 60 Human genes 0.000 title description 4
- 108010058432 Chaperonin 60 Proteins 0.000 title description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 35
- 230000007246 mechanism Effects 0.000 claims abstract description 15
- 230000002093 peripheral effect Effects 0.000 claims abstract description 8
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims abstract description 7
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims abstract description 7
- 210000003289 regulatory T cell Anatomy 0.000 claims abstract description 7
- 230000001404 mediated effect Effects 0.000 claims abstract description 6
- 206010011968 Decreased immune responsiveness Diseases 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 15
- 230000001939 inductive effect Effects 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 230000008646 thermal stress Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 53
- 210000004027 cell Anatomy 0.000 description 59
- 201000010099 disease Diseases 0.000 description 55
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 55
- 241001465754 Metazoa Species 0.000 description 51
- 102000004127 Cytokines Human genes 0.000 description 50
- 108090000695 Cytokines Proteins 0.000 description 50
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 44
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 44
- 102400000083 ADAM10-processed FasL form Human genes 0.000 description 35
- 101800001062 ADAM10-processed FasL form Proteins 0.000 description 35
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 35
- 241000700159 Rattus Species 0.000 description 31
- 206010003246 arthritis Diseases 0.000 description 28
- 239000000427 antigen Substances 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 27
- 102000036639 antigens Human genes 0.000 description 27
- 210000005087 mononuclear cell Anatomy 0.000 description 25
- 230000006698 induction Effects 0.000 description 20
- 230000004054 inflammatory process Effects 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 14
- 210000001503 joint Anatomy 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 12
- 238000011161 development Methods 0.000 description 12
- 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 11
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 11
- 208000023275 Autoimmune disease Diseases 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000010171 animal model Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 244000144993 groups of animals Species 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 230000008506 pathogenesis Effects 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 241001111421 Pannus Species 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 102000000503 Collagen Type II Human genes 0.000 description 6
- 108010041390 Collagen Type II Proteins 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 6
- 108010002352 Interleukin-1 Proteins 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000000845 cartilage Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 208000009386 Experimental Arthritis Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000003628 erosive effect Effects 0.000 description 5
- 238000007489 histopathology method Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229940122450 Altered peptide ligand Drugs 0.000 description 4
- 108010047620 Phytohemagglutinins Proteins 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000001885 phytohemagglutinin Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 101000883686 Homo sapiens 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 241000219061 Rheum Species 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 210000000270 basal cell Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012997 ficoll-paque Substances 0.000 description 3
- 102000046432 human HSPD1 Human genes 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002998 immunogenetic effect Effects 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 238000011694 lewis rat Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001258 synovial membrane Anatomy 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101100282617 Bovine herpesvirus 1.1 (strain Cooper) gC gene Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 206010023203 Joint destruction Diseases 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 101710107068 Myelin basic protein Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000001712 encephalitogenic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000399 optical microscopy Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010071155 Autoimmune arthritis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100021410 Heat shock 70 kDa protein 14 Human genes 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001041756 Homo sapiens Heat shock 70 kDa protein 14 Proteins 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 229940124084 Interleukin 1 antagonist Drugs 0.000 description 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 102000049772 Interleukin-16 Human genes 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100341510 Mus musculus Itgal gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 238000010161 Student-Newman-Keuls test Methods 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- MCRWZBYTLVCCJJ-DKALBXGISA-N [(1s,3r)-3-[[(3s,4s)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[(1s,4s)-5-[6-(trifluoromethyl)pyrimidin-4-yl]-2,5-diazabicyclo[2.2.1]heptan-2-yl]methanone Chemical compound C([C@]1(N(C[C@]2([H])C1)C(=O)[C@@]1(C[C@@H](CC1)N[C@@H]1[C@@H](COCC1)OC)C(C)C)[H])N2C1=CC(C(F)(F)F)=NC=N1 MCRWZBYTLVCCJJ-DKALBXGISA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000006450 immune cell response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108010091742 peptide F Proteins 0.000 description 1
- RJSZPKZQGIKVAU-UXBJKDEOSA-N peptide f Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C(C)C)C(C)C)C1=CC=CC=C1 RJSZPKZQGIKVAU-UXBJKDEOSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000008409 synovial inflammation Effects 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates to peptides of the human thermal stress protein of 60 kDa (in English 60 kDa heat shock protein, abbreviated Hsp ⁇ Oh) and derivatives thereof of the altered peptide ligand type (in English Altered Peptide Ligands, abbreviated APL).
- the invention relates to pharmaceutical compositions comprising such peptides for the treatment of Rheumatoid Arthritis (RA).
- RA is an autoimmune disease of unknown etiology that affects approximately 1% of the world's population. It is a syndrome characterized by chronic inflammation of the joints, although systemic manifestations can be observed. This disease begins with the inflammation of the synovial membrane and often leads to erosive destruction of the adjacent cartilage and bone, resulting in moderate physical disability of 80% of patients and early mortality (Moctezuma, JF (2002) Joint manifestations of rheumatoid arthritis, Mexican Journal of Rheumatology 17: 211-219). It can occur at any age, without distinctions of races or ethnic groups, but the maximum incidence of its onset occurs between 25 and 55 years of age.
- the cause of AR is unknown. It is known that it is a disease of multifactorial etiology, which involves the presence of genetic, environmental, immunological and hormonal factors. There are certain genes, which have a role in the immune system, associated with a tendency to develop RA. At the same time, some people with RA do not have these genes and others have them and never develop the disease. This has suggested that the genetic background of each person is important but not decisive.
- microbial antigens with a structure similar to their own antigens can trigger a cross response with their own tissue antigens producing an alteration in tolerance mechanisms and perpetuating an autoimmune response.
- the transition stage of lymphocytes between tolerance and immunity / autoimmunity is regulated at different levels.
- Two important parameters in this transition are the maturation state of the antigen presenting cells (in English Antigen Presenting CeIIs, abbreviated APC) and the levels of own antigens that are detected by the immune system (Ohashi, PS (2002) Making and breaking tolerance. Current Opinion in Immmunology 14: 744-759).
- the pathogenesis of RA is characterized by the concerted action of different types of cells that trigger the progressive destruction of cartilage and bone.
- inflammatory cytokines such as: TNF ⁇ , IL-1, IL-6, IL-15, IL-16, IL-17, IL-18 and IFN ⁇
- anti-inflammatories such as IL- 4, IL-11, IL-13 and antagonists of IL-1 or TNF ⁇ .
- this balance moves in favor of inflammatory cytokines (Arend, WP. (2001) Cytokine imbalance in the pathogenesis of rheumatoid arthritis: The role of interleukin-1 receptor antagonist. Semin Arthritis Rheum 30 (2): 1 -6)
- LFA1, ICAM-1 endothelial cells
- TNF ⁇ and IL-1 stimulate the proliferation of the synovial membrane that leads to the formation of pannus, can induce the differentiation of B lymphocytes to antibody producing cells, which potentially also participate in joint destruction. They also inhibit the production of anti-inflammatory cytokines (IL-4 and IL-14) produced by Th2 cells and stimulate hepatocytes to release IL-6.
- IL-4 and IL-14 anti-inflammatory cytokines
- IL-6 in turn favors the production of phase proteins. acute, which participate enhancing the immune response (Forre, O. (2000) New possibilities of treatment in AR. Scand J Rheumatol 29 (2) 73-84).
- Ia Hsp60 a protein that belongs to the family of Hsp, which are highly immunogenic proteins with an exceptional degree of evolutionary conservation.
- the immune response against foreign Hsp is an important defense mechanism against bacterial infections. Antibodies against these proteins may be abundant in normal subjects and in patients with autoimmune diseases and may cross-react with their own antigens (Chen, W. (1999) Human 60-kDa Heat-Shock Protein: A Danger Signal to the Innate Immune System. J lmmunol. 162: 3212-3219).
- the Hsp65 of Mt is homologous to the Hsp60 of mammals. It is suggested that Hsp60 can be recognized as an autoantigen in patients with RA. Comparing patients with osteoarthritis and patients with RA, the latter have an increase in the proliferative response of B lymphocytes in synovial fluid to mycobacterial Hsp65. The intensity of the response correlates with synovial inflammation. This response is not specific for RA compared to other inflammatory diseases (Life, P. (1993) Responses to Gram negative enteric bacterial antigens by synovial T cells from patiens with juvenile chronic arthritis: recognition of heat shock protein hsp60. J Rheumatol. 20: 1388-1396).
- a possible danger signal for the immune system constitutes Hsp, which are released from the dying cells, and which can induce an inflammatory response and initiate the maturation of APC. Being intracellular proteins, they are not highly expressed in the cell membrane, nor are they secreted, so they are attractive candidates for molecules that constitute danger signals (Van den Berg, WB. (1998): Joint inflammation and cartilage destruction may occur uncoupled Springer Semin Immunopathol. 20: 149-164).
- patent application W09610039 the use of a Mt Hsp60 peptide is proposed for the diagnosis and treatment of autoimmune arthritis.
- patent application WO9711966 it is proposed to use peptides from non-conserved regions of human Hsp60, which do not coincide with bacterial Hsp60, which could induce tolerance in the T cells of patients with RA.
- Patent application WO0143691 proposes the use of pharmaceutical preparations composed of peptides of the Hsp ⁇ Oh and variants thereof in the prevention of inflammatory diseases specifically for various autoimmune diseases including RA.
- US6180103 the use of an Hsp60 peptide named p277 and its analogues is proposed for the diagnosis and prevention of type I diabetes.
- the US5993803 patent protects the use of the Hsp60 protein, the p277 peptide and a group of peptides derived from said protein to reduce the severity of the immune response during organ transplantation. Recently it has been considered that atherosclerosis has a series of characteristics similar to autoimmune processes.
- WO0072023 a method is proposed for the treatment and diagnosis of atherosclerosis and coronary diseases using a preparation containing the Hsp60 protein.
- patent application WO02057795 a new method for the diagnosis and treatment of osteoporosis is protected using proteins of the Hsp family and pathogen proteins such as viruses and bacteria.
- Oral tolerization has been proposed as a method of creating peripheral tolerance against certain antigens. This can be induced by active suppression mechanisms or by anergy or clonal deletion, depending on the dose and frequency of the administration of the antigen.
- the method can induce regulatory T cells that are specifically activated with the antigen, but that exert their action independently (active suppression). In order for the regulatory action to occur, it is not necessary to administer the supposedly pathogenic antigen, but another one capable of inducing active suppression in the inflammatory focus, inhibiting the activity of pathogenic effector cells.
- Type II collagen abbreviated IIC is the autoantigen that has been most used in this regard.
- a peptide of Hsp70 a protein belonging to the family of Hsp
- Another variant that has been suggested to induce tolerance is through APL peptides, based on the fact that T cells are activated if CD 4 + T lymphocytes specific to a particular peptide antigen recognize the antigen presented by competent APCs.
- TcR short T cell receptor
- the APLs are analogs of immunogenic peptides with one or several substitutions in the essential contact positions with the TcR or with the major incompatibility complex (in English Major Histocompatibility Complex, abbreviated MHC), which interfere with or modify the cascade of events necessary for Ia Complete activation of T cells.
- MHC Major Histocompatibility Complex
- APLs with properties similar to the immunogenic peptide (agonists) can be designed, whose effects include increasing the response of T cells to specific antigens. This effect is advantageous in pathological conditions such as neoplastic and infectious diseases.
- Peptides with antagonistic properties to the immunogenic peptide can also be designed that could be beneficial in the control of autoimmune diseases since they can block the T cell response by acting as TcR antagonists (M De Magistris (1992) Antigen analog-major complex histocompatibility complexes act as antagonist of the T cell receptor. Cell 68: 625- 634), partial agonists or inducing a population of regulatory T cells that mediate active suppression (Evavold, BD (1991) Separation of IL-4 production from Th cell proliferation by an altered T cell ligand. Science 252: 1308-1310).
- TcR antagonists M De Magistris (1992) Antigen analog-major complex histocompatibility complexes act as antagonist of the T cell receptor. Cell 68: 625- 634
- partial agonists or inducing a population of regulatory T cells that mediate active suppression (Evavold, BD (1991) Separation of IL-4 production from Th cell proliferation by an altered T cell ligand
- APL type peptides derived from epitope were used, covering amino acids 83 to 93 of the MBP (myelin basic protein, abbreviated MPB).
- MPB myelin basic protein
- One of these trials included 142 patients with multiple sclerosis, and was suspended because 9% of the patients developed hypersensitivity (Ludwig Kapposi (2000) Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo controlled, randomized phase Il trial. Nat ⁇ re Medicine 10: 1176-1182).
- the main challenge in the treatment of autoimmune diseases is the development of therapeutic strategies that can delegate pathogenic T cells with specificity, without affecting other unrelated T cells. Therefore, the therapeutic search must find a safe, specific and effective way to turn off an advanced autoimmune process.
- the present invention in contrast to the prior art, proposes the use of Hsp ⁇ Oh peptides and derivatives thereof of the APL type, which specifically induce molecular inhibitory mechanisms of the AR course.
- the present investment solves the aforementioned problem, providing peptides of the human 60 kDa thermal stress protein that constitute epitopes for T cells, to induce peripheral tolerance mechanisms, in particular anergy inducing mechanisms or mediated by regulatory T cell clones in patients with RA and presenting the sequences:
- SIDLKDKKYKNIGAKLVQDVANNTNEEA (SEQ. ID. NO: 2) 1 2 3 4 5 6 7 8 is replaced in position 1 by L 1 I 1 V 1 M 1 Y 1 W 1 F, or A position 2 by A 1 D 1 E 1 F 1 G 1 H 1 I 1 K 1 L 1 M 1 N 1 Q 1 R 1 S 1 T 1 V 1 W, or Y position 3 by A 1 F 1 I 1 K 1 L 1 M 1 P 1 R 1 S 1 T 1 V 1 W 1 or Y position 4 by L 1 I 1 V 1 M 1 Y 1 W 1 F, or A position 5 by A 1 D 1 E 1 F 1 G 1 H 1 LK 1 L 1 M 1 N 1 Q 1 R 1 S 1 T 1 V 1 W, or Y position 6 by A 1 D 1 E 1 F 1 G 1 H 1 I 1 K 1 L 1 M 1 N 1 Q 1 R 1 S 1 T 1 V 1 W 1 or Y position 7 by A 1 F 1 I 1 K 1 L 1 M 1 P 1 R 1 S 1 T 1 V 1 W 1 or
- the APL type derived peptides have an amino acid sequence selected from the group consisting of SEQ. ID. NO: 4, SEQ. ID. NO: 5, SEQ. ID. NO: 6, SEQ. ID. NO: 7, SEQ. ID. NO: 8, SEQ. ID. NO: 9, SEQ. ID. NO: 10, SEQ. ID. NO: 11, SEQ. ID. NO: 12, SEQ. ID. NO: 13, SEQ. ID. NO: 14, SEQ. ID. NO: 15, SEQ. ID. NO: 16, SEQ. ID. NO: 17, SEQ. ID. NO: 18, SEQ. ID. NO: 19, SEQ. ID. NO: 20 and SEQ. ID. NO: 21.
- the peptides of the present invention can be produced by routine methods of peptide synthesis. Each composition that has a specific peptide can be tested for the level and quality of the immune response that induces in experiments such as those described in the examples that will be presented later.
- the invention also includes pharmaceutical compositions comprising one or more of the above-listed peptides and optionally a pharmaceutically acceptable carrier or excipient.
- the administration of pharmaceutical preparations to patients should be in correspondence with the HLA class II molecules expressed by the patient in question.
- compositions will depend on the cytokine pattern induced by said preparations in the "ex vivo" assays.
- Pharmaceutical preparations containing APL peptides inducing a regulatory response will be administered intradermally or subcutaneously.
- Pharmaceutical preparations containing the original inducing peptides of a TH1 response may be administered orally.
- the amounts present in the pharmaceutical compositions of the present invention are those that produce the effective immune response in the host.
- the effective amount is the amount that when administered results in the induction of molecular mechanisms that significantly decrease the inflammatory signs characteristic of RA and stop the histopathological joint damage characteristic of the course of this disease.
- the amount of the pharmaceutical composition administered to the host may vary depending on several factors that include: the peptides used, ACR score (in English, American College of Rheumatology, abbreviated ACR), HLA type II, time of diagnosis of the disease, age , sex, general health, as well as the level of immune response in general.
- the present invention also relates to a method of treatment of RA, which comprises administering to a patient effective amounts of the peptides or pharmaceutical compositions referred to above.
- Figure 1 Evaluation of the clinical signs of Arthritis in rats treated with peptides F19-6 and F19-7 intradermally, in the AIA model.
- Figure 2 Modulation of the levels of TNF ⁇ induced by peptides F19-6 and F19-5 7 in mononuclear cells of rats of the AIA model on day 15 after the disease was induced.
- Figure 3 Modulation of the levels of IL-10 induced by peptides F19-6 and F19-7 in mononuclear cells of rats of the AIA model on day 15 after 10 induced the disease.
- Figure 4 Optical microscopy of a section of the joint belonging to an untreated sick animal.
- Figure 5 Optical microscopy of a section of the joint belonging to an animal treated with the F19-7 peptide intradermally.
- Figure 7 Modulation of the levels of IL-10 by peptides F19-6 and F19-7 in 5 mononuclear cells of rats of the animal model of collagen-induced arthritis, on day 21 after and induced the disease.
- Figure 8 Modulation of TNF ⁇ levels by peptides F19-6 and F19-7 in mononuclear cells of patients with RA. 0
- Figure 9 Modulation of TNF ⁇ levels by peptides E18-3 and E18-12 in mononuclear cells of patients with RA.
- Figure 10 Modulation of IL-10 levels by peptides E18-3 and E18-12 in mononuclear cells of patients with RA.
- Figure 11 Modulation of IL-10 levels induced by peptides E18-3 and E18-12 and their APLs in mononuclear cells of patients with RA.
- Figure 12 Modulation of TNF ⁇ levels induced by peptides E18-3 and E18-12 and their APLs in mononuclear cells of patients with RA.
- Figure 13 Relationship of IL-10 and TNF ⁇ levels, induced by peptides E18-3 and E18-12 and their APLs.
- Figure 14 Evaluation of the clinical signs of Arthritis in rats treated with peptides E18-12 and E18-12APL1 intradermally, in the AIA model.
- Example 1 Hsp ⁇ Oh peptides presented by human HLA.
- Hsp ⁇ Oh peptides reported as human T cell epitopes were selected by the two programs used: SYFPEITHI (Hans-Georg Rammensee, Jutta Bachmann, Niels Nikolaus Emmerich, Oskar Alexander Bachor, Stefan Stevanovic. 1999. Immunogenetics 50: 213-219 SYFPEITHI: datábase for MHC ligands and peptide motifs. (Access via: http://www.uni-tuebingen.de/uni/kxi/)) and ProPred (Singh, H. And Raghava.GPS 2001. ProPred: Prediction of HLA-DR binding sites Bioinformatics, 17 (12): 1236-37). The sequence corresponding to these peptides is shown in Table 1.
- Example 2 Hsp ⁇ Oh peptide for epitope of Lewis rats.
- Example 3 Design of the APL with modifications in the amino acids involved in the binding to the MHC.
- position 1 is replaced by: A 1 F 1 I 1 L 1 M 1 V 1 W, or Y position 2 is replaced by: A 1 D 1 E 1 F 1 G 1 H 1 I 1 K 1 L 1 M 1 N 1 Q 1 R 1 S 1 T 1 V 1 W 1 or Y position 3 is replaced by: A 1 K 1 V 1 R 1 T 1 I 1 P 1 L 1 N 1 S 1 G 1 Y, or M position 4 is replaced by: A 1 D 1 E 1 F 1 G 1 H 1 I 1 K 1 L 1 M 1 N 1 Q 1 R 1 S 1 T 1 V 1 W 1 or Y position 5 is replaced by: A 1 D 1 E 1 F 1 G 1 H 1 I 1 K 1 L 1 M 1 N 1 Q 1 R 1 S 1 T 1 V, or Y position 6 is replaced by: A 1 D 1 E 1 F 1 G 1 H 1 I 1 K 1 L 1 M 1 N 1 P 1 Q 1 R 1 S 1 T 1 V 1 W 1 or Y position 7 is replaced by: A 1 D 1 E 1 F 1 G 1 H 1 I 1 K 1 L 1 M 1
- position 1 is replaced by: L 1 I 1 V 1 M 1 Y 1 W 1 F, or A position 2 is replaced by: A 1 D 1 E 1 F 1 G 1 H 1 I 1 K 1 L 1 M 1 N 1 Q 1 R 1 S 1 T 1 V 1 W 1 or Y position 3 is replaced by: A 1 F 1 I 1 K 1 L 1 M 1 P 1 R 1 S 1 T 1 V 1 W, or Y position 4 is replaced by: L 1 I 1 V 1 M 1 Y 1 W 1 F 1 or A position 5 is replaced by: A 1 D 1 E 1 F 1 G 1 H 1 I 1 K 1 L 1 M 1 N 1 Q 1 R 1 S 1 T 1 V 1 W 1 or Y position 6 is replaced by: A 1 D 1 E 1 F 1 G 1 H 1 I 1 K 1 L 1 M 1 N 1 Q 1 R 1 S 1 T 1 V 1 W 1 or Y position 7 is replaced by: A 1 F 1 I 1 K 1 L 1 M 1 P 1 R 1 S 1 T 1 V 1 W 1 or Y position 8 is replaced by:
- the F19-6 peptide has been substituted in positions 1 and 2 indicated below by the amino acids specified:
- Example 4 Induction of arthritis by adjuvant and collagen in Lewis rats.
- soviet female Lewis rats were used (hapiotype RT1.BI MHC) supplied by the National Center for Laboratory Animal Production (CENPALAB, Cuba). The rats were randomly selected, weighing approximately 101-120 g and 5-8 weeks of age.
- One of the agents inducing the disease used was Mt (H37Ra, Difco, England) in Freund's incomplete adjuvant (AIF) (Sigma, USA).
- the other agent that induces arthritis was the bovine type II collagen in AIF.
- Example 5 Evaluation of clinical signs. The degree of inflammation associated with the development of the arthritis presented by each rat was evaluated with the following average prepared for this purpose:
- the peptides were synthesized by the Fmoc / tBu strategy in syringes.
- the Fmoc-AM-MBHA resin (0.54 mmoL / g) was used and the synthesis protocol was followed with mechanical agitation. After treatment with TFA, the peptide was lyophilized and characterized by HPLC and mass spectrometry.
- Example 7 Intradermal administration of the peptides.
- the animals were separated into four groups of 12 rats each.
- the disease was induced in three groups of animals (Group I-Group III), of which two were treated with the peptides and one remained as control of the induction of the disease.
- the two groups of animals that were treated with the peptides were administered 200 ⁇ g of peptide per rat in a volume of 100 ⁇ L of PBS, on days 12, 17 and 22 after induced disease with Mt. Animals separated in Four groups were treated as follows:
- Example 8 Isolation of messenger ribonucleic acid (mRNA).
- the mRNA was isolated following the protocol recommended by the manufacturer.
- Example 9 Reverse transcription of ribonucleic acid.
- the Gene Amp RNA PCR Kit system was used to obtain the complementary DNA
- thermocycler Minicycler, MJ Research, USA
- Example 10 Polymerase chain reaction.
- the polymerase chain reaction (abbreviated CPR) was performed for the cytokines: TNF ⁇ and IL-10 and the constitutive gene coding for the enzyme GAP-DH (in English glyceraldehyde-3-phosphate dehydrogenase, abbreviated GAP-DH).
- each primer 5 ⁇ l_ of the template DNA, 0.25 ⁇ l_ of the Thermostable DNA Polymerase (Taq-Pol) (Perkin-Elmmer, USA) were used in the buffer recommended by the manufacturers (KCI 50Mm, Tris-HCI 1OmM, pH 9.0, 0.1% Triton X-100 and MgCI 2 1.5 mM) in a final volume of 25 ⁇ l_.
- thermocycler Minicycler, MJ Research, USA
- a first cycle of 3 minutes at 94 0 C (denaturation temperature), 1 minute at 94 0 C, 1 minute 58 0 C (hybridization temperature) and 1 minute at 72 0 C (elongation temperature) then 35 cycles of: 1 minute at 94 0 C, 1 minute at 58 0 C and 1 minute at 72 0 C each .
- a 3 minute extension step at 72 0 C a 3 minute extension step at 72 0 C.
- Example 11 Analysis of CPR products by electrophoresis in agarose gels.
- the result of the CPR products was checked by agarose gel electrophoresis.
- the images of the electrophoretic runs were captured and analyzed with the Molecular Analyst (BioRad) program.
- the results were expressed as relative levels of mRNA for each cytokine.
- Example 12 Statistical analysis of the relative levels of mRNA for each cytokine.
- IL-10 is involved in the induction of peripheral tolerance through a response mediated by T cells. It is known that it directly regulates T cells by inhibiting the production of IL-2, IL-5 and TNF ⁇ .
- Figure 3 shows the semi-quantitative measurement of the expression levels of IL-10 in the different treatment groups, on the 15th day after the induction of the disease.
- Gl corresponds to the animals treated with the F19-6 peptide
- GII represents the group of rats treated with the F19-7 peptide
- GIII represents the group of untreated diseased animals
- GIV includes the healthy animals.
- the treatment of the animals with the peptides induces an increase in the relative expression levels of IL-10.
- No statistically significant differences were obtained between the two groups of animals treated with the peptides, there being significant differences between these two groups and the animals that constituted the positive and negative controls of the assay. From these results we can infer that the peptides act by inducing a change in the functional phenotype of the T cells involved in the pathogenesis of the disease, increasing the levels of production of anti-inflammatory cytokines as is the case of IL-10 and decreasing the production levels of proinflammatory cytokines such as TNF ⁇ .
- Example 13 H ⁇ stopathological analysis.
- the plates corresponding to the joints were analyzed by the group of
- the joints were fixed in 10% neutral formalin buffer and decalcified.
- the tissues were dehydrated in a gradient of alcohol, embedded in paraffin and cut into sections of 5 ⁇ m. Subsequently, the samples were mounted on slides and stained with a hematoxylin-eosin mixture and observed in an optical microscope.
- Figure 4A corresponds to the articulation of an untreated group III animal. In this, the presence of the pannus that invades the entire intra-articular space can be observed, extending towards the cartilage where the erosion of this is evidenced, as well as the invasion towards the bone marrow.
- Figure 4B shows an enlargement of the region that corresponds to the bone marrow where the pannus that is a granulation tissue rich in phagocytic cells is more clearly observed.
- Example 14 In vitro evaluation of the cytokine pattern against peptides F19-6 and F19-7, using rat mononuclear cells where Arthritis was induced with type II collagen.
- Mononuclear cells isolated from the spleen were cultured in 1.5 mL of RPMI 1640 in 24-well plates (Costar, USA). The assay was performed in triplicate, and a total of 3x10 6 cells / well were cultured for 24 hours with the peptides
- Cells grown without the peptides were used as a negative control of the assay.
- the mRNA was isolated, the reverse transcription reaction of the nucleic acid and the CPR was performed in the same manner as described in the previous examples.
- the analyzes of the PCR products were carried out by electrophoresis in agarose gels as described in example 12. To determine the differences in the cytokine pattern according to the relative levels of mRNA for each of the samples, statistical tests were used described in example13.
- Figure 6 shows the TNF ⁇ levels of cells grown without peptide and stimulated with peptides F19-6 and F19-7 in vitro corresponding to the 21st day after the induction of the disease
- letter A represents the levels of TNF ⁇ In cultured cells without peptide
- letter B represents the values of this cytokine when cells are stimulated with peptides F19-6
- letter C corresponds to levels of TNF ⁇ when cells are stimulated with peptides F19-7.
- CII represents the group of animals, where Arthritis was induced with collagen type Il and Control represents the group of healthy animals.
- Figure 7 shows the IL-10 levels of cells grown without peptide and stimulated with peptides F19-6 and F19-7 in vitro corresponding to the 21st day after the induction of the disease
- letter A represents the levels of IL-10 in cultured cells without peptide
- letter B represents the values of this cytokine when cells are stimulated with peptides F19-6
- letter C corresponds to levels of IL-10 when cells are stimulated with F19-7 peptides.
- CII represents the group of animals, where the AR was induced with collagen type Il and Control represents the group of healthy animals.
- F19-6 and F19-7 peptides in vitro decrease TNF ⁇ levels, in the case of IL-10 levels only F19-7 Io peptide increases significantly.
- F19-7 peptide is capable of modulating the cytokine pattern towards a regulatory phenotype in the animal model where Arthritis is induced with collagen. Therefore we can affirm that the immunomodulatory action of this peptide derived from Hsp ⁇ Oh in vitro can be extended to animal models of Arthritis, where the inducing agent that participates in the development of the disease is not Mt or related autoantigens.
- Example 15 Measurement of cytokines in patients with RA against peptides F19-6 and F19-7. Using blood from patients with RA, cytokine measurement assays were performed: TNF ⁇ , IFN ⁇ and IL-10. In these trials, the potential of the Hsp ⁇ Oh peptides was evaluated to increase or decrease the different cytokines involved in the pathogenesis of the disease. 10 mL of blood was taken from each patient, which was diluted ⁇ A in 1X PBS. 5 mL of this dilution was added to 3 mL of Ficoll-Paque (Amershan) in 15 mL centrifuge tubes, which were centrifuged for 30 min. at 1200 rpm.
- Ficoll-Paque Amershan
- the ring corresponding to the mononuclear cells was removed. Subsequently the cells were washed twice with 15 mL of 1X PBS and after each wash they were centrifuged at 900 rpm. Finally, the precipitate was resuspended in RPMI 1640 medium containing 10% fetal bovine serum and supplemented with penicillin (100U / mL), streptomycin (100 ⁇ g / mL), 25 mM / L HEPES and 2mM L-glutamine (all acquired from Gibco BRL) .
- the mononuclear cells obtained were seeded in number of 10 6 cells / well in 24-well plates (Costar) in a volume of 800 ⁇ L. Subsequently, the Hsp ⁇ Oh peptides were added in a concentration range from 0.5 ⁇ g / mL to 100 ⁇ g / mL, with the optimum concentration for modulating cytokine levels being specified for each peptide.
- Phytohemagglutinin (PHA) 1% was used as a positive control of cell stimulation, while RPMI 1640 was only used as a control of basal cell growth.
- FIG. 8 shows the levels of TNF ⁇ modulated by peptides F19-6 and F19-7 in mononuclear cells of patients with RA.
- the letter C represents cells grown in vitro without peptides; while F19-6 correspond to cells stimulated in vitro with peptide F19-6 and F19-7 represents cells stimulated in vitro with peptide F19- 7.
- Example 16 Cytokine measurement in patients with RA against peptides E18-12 and E18-3. Using blood from patients with RA, cytokine measurement assays were performed: TNF ⁇ , IFN ⁇ and IL-10. In these tests, the potential of the Hsp ⁇ Oh peptides was evaluated to increase or decrease the different cytokines involved in the pathogenesis of the disease. 10 mL of blood was taken from each patient, which was diluted Vi in 1X PBS. 5 mL of this dilution was added to 3 mL of Ficoll-Paque (Amershan) in 15 mL centrifuge tubes, which were centrifuged for 30 min. at 1200 rpm.
- Ficoll-Paque Amershan
- the ring corresponding to the mononuclear cells was removed. Subsequently the cells were washed twice with 15 mL of 1X PBS and after each wash they were centrifuged at 900 rpm. Finally, the precipitate was resuspended in RPMI 1640 medium containing 10% fetal bovine serum and supplemented with penicillin (100U / mL), streptomycin (100 ⁇ g / mL), 25 mM / L HEPES and 2mM L-glutamine (all acquired from Gibco BRL ). The mononuclear cells obtained were seeded in number of 10 6 cells / well in 24-well plates (Costar) in a volume of 800 ⁇ L.
- Hsp ⁇ Oh peptides were added in a concentration range from 0.5 ⁇ g / mL to 100 ⁇ g / mL, with the optimum concentration for modulating cytokine levels being specified for each peptide.
- Phytohemagglutinin (PHA) 1% was used as a positive control of cell stimulation, while RPMI 1640 was only used as a control of basal cell growth.
- the cells were cultured for 24 hours and subsequently the supernatant of each well, diluted V, was taken, and the concentration of the cytokines was determined through the specific kits for each of them Quantikine ® (R&D Systems) according to the manufacturers recommendations .
- Figure 9 shows the levels of TNF ⁇ modulated by peptides E18-3 and E18-12 in mononuclear cells of patients with RA.
- the patients represented by P4, P5 and P16 express the DR 0306 molecule
- the patients identified as P7, P8 and P12 express the DR 0303 molecule
- the P9 patient has a DR 0506 genotype
- the P10 patient has a DR 0204 genotype.
- the letter C represents cells cultured in vitro without peptides
- E18-3 corresponds to cells stimulated in vitro with peptide E18-3
- E18-12 represents cells stimulated in vitro with peptide E18- 12.
- a therapeutic variant of the original peptides: E18-12 or E18-3 could be the administration of these by oral route, in such a way that they induce antigenic tolerization mechanisms, which will contribute significantly to the decrease of the inflammation.
- Example 17 Cytokine measurement in patients with RA versus APL-derived peptides.
- MGPKGRTVIIEQSLGSPKVTK (SEQ. ID. NO: 8) MGPKGRTVIIEQSMGSPKVTK (SEQ. ID. NO: 9)
- MGPKLRTVIILQSMGSPKVTK SEQ. ID. NO: 13
- SIDLKDKLKNIGAKLVQDVANNTNEEA SEQ. ID. NO: 14
- SIDLKDKYKNIGAKLVQLVANNTNEEA SEQ. ID. NO: 18
- SIDLKDKYKNIGAKLVQAVANNTNEEA SEQ. ID. NO: 19
- the mononuclear cells obtained were seeded in number of 10 6 cells / well in 24-well plates (Costar) in a volume of 800 ⁇ L.
- the cells were stimulated with the peptides [E18-3, E18-12, E18-3APL1 (SEQ. ID. NO: 18), E18-3APL2 (SEQ. ID. NO: 21), E18-12APL1 (SEQ. ID. NO: 5), E18-12APL3 (SEQ. ID. NO: 12)], at a concentration of 40 ⁇ g / mL and in triplicate.
- RPMI 1640 was only used as a control of basal cell growth.
- Cells were cultured for 24 hours and later supernatants of each well were taken, diluted ⁇ A and the concentration of cytokines were determined by specific kits for each Quantikine ® (R & D Systems) as recommended by the Manufacturers
- Figure 11 shows the levels of IL-10 induced by the original peptides (E18-12 and E18-3) and the panel of APL type peptides: E18-3APL1 (SEQ. ID. NO: 18); E18-3APL2 (SEQ. ID. NO: 21); E18-12APL1 (SEQ. ID. NO: 5); E18-12APL3 (SEQ. ID. NO: 12).
- the letters indicate statistically significant differences (only the statistical significance between the different peptides and the control cells of each patient is referred to individually).
- the cells of patients P4 and P6 were not stimulated with peptides E18-3APL2 and E18-12APL3.
- the E18-3APL1 peptide significantly increases IL-10 levels with respect to unstimulated cells.
- the increase induced by this peptide in some of the patients, such as P2 and P4 was up to 9 times the amount produced by the unstimulated cells and in patients such as P1, P3 and P5 up to 5 times higher.
- Similar results were generally obtained with the E18-12APL1, showing a significant increase in the levels of IL-10 in patients P1, P4 and P6.
- neither the original peptides nor the E18-3APL2 and E18-12APL3 peptides induced an increase in IL-10 levels compared to the cells that represent the negative control.
- the levels of TNF ⁇ induced by the different peptides in the same group of patients are represented.
- the letters indicate statistically significant differences (only the statistical significance between the different peptides and the control cells of each patient is referred to individually).
- the cells of patients P4 and P6 were not stimulated with peptides E18-3APL2 and E18-12APL3.
- all patients do not respond with the same intensity to the stimulation with the different peptides, although it should be noted that the response was quite homogeneous.
- the peptide that most increased the production of TNF ⁇ was E18-12APL1, especially in patients P4 and P5, while in patients P1, P2 and P3 showed a slight increase with respect to the negative control.
- the peptide E18-3APL1 had a similar behavior in most of the patients.
- the cells of patients P2, P4 and P5 were the ones that most evidenced the increase in TNF ⁇ levels, although their increase was less marked. Similar results were obtained in this test with the original peptides as in previous evaluations. The previous results indicate that no peptide or its APL induces a decrease in the expression of TNF ⁇ in the mononuclear cells of the patients. These results could be contradictory, since the same APLs that increase the production of IL-10 promote an increase in TNF ⁇ levels.
- Figure 13 shows the relationship of the levels of IL-10 and TNF ⁇ induced by the peptides and their APLs.
- the letters indicate statistically significant differences (only the statistical significance between the different peptides and the control cells of each patient is referred to individually).
- the cells of patients P4 and P6 were not stimulated with peptides E18-3APL2 and E18-12APL3. It is evident that the increase in IL-10 with respect to that of TNF ⁇ was considerably higher, since in four of the six patients, cells stimulated with E18-3APL1 showed an index greater than 1, which indicates that IL-10 levels exceeded those of TNF ⁇ .
- the levels of IL-10 were considerably higher in cells stimulated with the E18-3APL1 peptide with respect to the cells that constituted the negative control, showing statistically significant differences.
- E18-12APL1 the differences in comparison to the negative control were not so remarkable. So it can be ensured that although E18-3APL1 increases TNF ⁇ levels, the predominant net effect is the increase in IL-10 levels, which translates into a polarization of the response in favor of immunosuppressive cytokines .
- the present invention has as a fundamental advantage the use of pharmaceutical preparations containing immunomodulatory peptides of the human Hsp60 stress protein, corresponding to T-cell epitopes or APL-like variants of these peptides, which can be used effectively in the treatment of patients with RA, inducing a specific immune response aimed at silencing the clones of autoreactive T cells involved in the immunopathogenic mechanisms of this disease.
- the treatment that we propose in this invention is affordable and can be extended to a large number of patients and can also be used in combination with current therapies for this disease.
- Example 18 Evaluation of the therapeutic effect of APL-derived peptides, in an animal model where arthritis is induced with Me.
- the animals were separated into twelve groups of eight rats each.
- the disease was induced in eleven groups of animals (Group I-Group Xl), of which ten were treated with the peptides and one remained as control of the induction of the disease.
- the groups of animals that were treated with the peptides were administered 50 ⁇ g of peptide per rat in a volume of 100 ⁇ L of PBS, on days 12, 14, 16,18, 20, 22, 24 and 26 after induced The disease with Mt
- the animals separated into twelve groups were treated as follows:> group I: the peptide E18-12 was administered (SEQ. ID. NO: 1)
- group X the peptide corresponding to: SEQ was administered. ID. NO: 17 > group XI: no peptide was administered (control of the induction of the disease)
- Group XII the disease was not induced or peptide was administered (negative control).
- Figure 14 shows the graph of the evolution of the disease in four groups of animals belonging to this biomodel.
- the groups shown are: group I (animals treated with E18-12), group Il (animals treated with E18-12APL1, SEQ. ID. NO: 5), group Xl (control of induction of Ia disease) and group XII (healthy animals).
- group I animals treated with E18-12
- group Il animals treated with E18-12APL1, SEQ. ID. NO: 5
- group Xl control of induction of Ia disease
- group XII healthy animals.
- different letters indicate significant differences (p ⁇ 0.001) (refers to the statistical significance between all groups on the specific days of measurement).
- the animals of groups I, Il and Xl began to show the clinical signs of RA.
- Many animals also presented extra-articular manifestations such as nodules in the ears, in the tail and in the extremities.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020077008682A KR101054332B1 (ko) | 2004-09-24 | 2005-09-22 | Hsp60의 펩티드 및 이들의 유도형 apl 및 약학적조성물 |
EP05794474A EP1803732B1 (en) | 2004-09-24 | 2005-09-22 | Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions |
MX2007003624A MX2007003624A (es) | 2004-09-24 | 2005-09-22 | Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas. |
ES05794474T ES2386498T3 (es) | 2004-09-24 | 2005-09-22 | Péptidos y derivados tipo APL de Hsp60 y composiciones farmacéuticas |
BRPI0515893A BRPI0515893B8 (pt) | 2004-09-24 | 2005-09-22 | peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica. |
BR122018077204A BR122018077204B8 (pt) | 2004-09-24 | 2005-09-22 | peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica |
DK05794474.6T DK1803732T3 (da) | 2004-09-24 | 2005-09-22 | Peptider og derivater af APL-TYPE af HSP60 og famaceutiske sammensætninger |
AT05794474T ATE546462T1 (de) | 2004-09-24 | 2005-09-22 | Peptide und derivate vom apl-typ von hsp60 und pharmazeutische zusammensetzungen |
AU2005287757A AU2005287757B2 (en) | 2004-09-24 | 2005-09-22 | Peptides and APL-type derivatives of Hsp60 and pharmaceutical compositions |
JP2007532752A JP4755649B2 (ja) | 2004-09-24 | 2005-09-22 | Hsp60のペプチド及びapl型誘導体並びに医薬組成物 |
CN2005800403891A CN101065398B (zh) | 2004-09-24 | 2005-09-22 | Hsp60的肽和apl型衍生物及药物组合物 |
CA2581110A CA2581110C (en) | 2004-09-24 | 2005-09-22 | Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions |
US11/663,603 US8383771B2 (en) | 2004-09-24 | 2005-09-22 | Altered peptide ligand derived from HSP60 and pharmaceutical compositions |
US12/649,687 US8324164B2 (en) | 2004-09-24 | 2009-12-30 | Peptides and altered peptide ligands derived from HSP60 and pharmaceutical compositions |
AU2010219312A AU2010219312B2 (en) | 2004-09-24 | 2010-09-06 | Peptides and APL-type derivatives of HSP60 and pharmaceutical compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20040207A CU23504A1 (es) | 2004-09-24 | 2004-09-24 | Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas |
CU2004-0207 | 2004-09-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/663,603 A-371-Of-International US8383771B2 (en) | 2004-09-24 | 2005-09-22 | Altered peptide ligand derived from HSP60 and pharmaceutical compositions |
US12/649,687 Division US8324164B2 (en) | 2004-09-24 | 2009-12-30 | Peptides and altered peptide ligands derived from HSP60 and pharmaceutical compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006032216A2 true WO2006032216A2 (es) | 2006-03-30 |
WO2006032216A3 WO2006032216A3 (es) | 2007-05-18 |
Family
ID=40273413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2005/000008 WO2006032216A2 (es) | 2004-09-24 | 2005-09-22 | Peptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas |
Country Status (17)
Country | Link |
---|---|
US (2) | US8383771B2 (es) |
EP (2) | EP1803732B1 (es) |
JP (1) | JP4755649B2 (es) |
KR (2) | KR101035283B1 (es) |
CN (2) | CN101065398B (es) |
AR (2) | AR051928A1 (es) |
AT (1) | ATE546462T1 (es) |
AU (2) | AU2005287757B2 (es) |
BR (2) | BR122018077204B8 (es) |
CA (2) | CA2797769C (es) |
CU (1) | CU23504A1 (es) |
DK (2) | DK1803732T3 (es) |
ES (2) | ES2445707T3 (es) |
MX (1) | MX2007003624A (es) |
RU (1) | RU2361877C2 (es) |
WO (1) | WO2006032216A2 (es) |
ZA (1) | ZA200702938B (es) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010075824A1 (es) | 2008-12-29 | 2010-07-08 | Centro De Ingeniería Genética Y Biotecnología | Uso de peptido tipo apl para el tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i |
CN101687912B (zh) * | 2007-01-30 | 2014-01-22 | 埃皮瓦克斯公司 | 调节性t细胞表位、组合物及其用途 |
WO2019129315A1 (es) | 2017-12-29 | 2019-07-04 | Centro De Ingenieria Genetica Y Biotecnologia | Composición farmaceutica que comprende un peptido tipo apl |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8680241B2 (en) * | 2009-09-06 | 2014-03-25 | Protab Ltd. | Humanized antibodies specific for HSP65-derived peptide-6 methods and uses thereof |
WO2011059758A2 (en) * | 2009-10-28 | 2011-05-19 | Argentis Pharmaceuticals, Llc | Apls for treating arthritis |
CU20200026A7 (es) * | 2020-04-13 | 2021-11-04 | Ct Ingenieria Genetica Biotecnologia | Péptido para el tratamiento del síndrome de la tormenta de citocinas |
CN111870697B (zh) * | 2020-09-18 | 2022-09-09 | 山东鲁抗医药股份有限公司 | 糖类物质在提高apl型衍生肽稳定性中的应用和冻干组合物 |
KR102333645B1 (ko) | 2021-07-27 | 2021-12-02 | (주)문화전기 | 각도조절이 용이한 엘이디조명시스템 |
CN115671253B (zh) * | 2021-07-30 | 2024-02-27 | 河北菲尼斯生物技术有限公司 | Se-dr亲和肽在制备治疗风湿疾病的药物中的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000072023A2 (en) | 1999-05-21 | 2000-11-30 | Semmelweis University Of Medicine | Diagnosis and treatment of atherosclerosis and coronary heart disease |
WO2002057795A2 (en) | 2001-01-19 | 2002-07-25 | Cambridge Scientific, Inc. | Methods of diagnosis and treatment of osteoporosis |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8701163A (nl) | 1986-09-09 | 1988-04-05 | Nederlanden Staat | Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits. |
NL8703107A (nl) | 1987-12-22 | 1989-07-17 | Nederlanden Staat | Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten. |
US5773570A (en) | 1994-05-20 | 1998-06-30 | The Regents Of The University Of California | Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis |
GB9419553D0 (en) | 1994-09-27 | 1994-11-16 | Univ Bristol | Polypeptides and their use in the treatment of auto-immune disease |
US6180103B1 (en) | 1994-12-21 | 2001-01-30 | Yeda Research And Development Co., Ltd. | Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes |
GB9519737D0 (en) | 1995-09-27 | 1995-11-29 | Peptide Therapeutics Ltd | Polypeptides and their use in treatment and prophylaxis of auto-immune |
US5993803A (en) | 1996-08-30 | 1999-11-30 | Yeda Research And Development Co., Ltd. | Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity |
US20020169302A1 (en) * | 1999-08-23 | 2002-11-14 | Genesis Research And Development Corp. Ltd. | Compositions isolated from bovine mammary gland and methods for their use |
EP1237570A4 (en) * | 1999-12-15 | 2005-01-05 | Peptor Ltd | FRAGMENTS AND ANTAGONISTS OF THERMAL SHOCK PROTEINS 60 |
-
2004
- 2004-09-24 CU CU20040207A patent/CU23504A1/es active IP Right Grant
-
2005
- 2005-09-21 AR ARP050103950A patent/AR051928A1/es active IP Right Grant
- 2005-09-22 BR BR122018077204A patent/BR122018077204B8/pt active IP Right Grant
- 2005-09-22 MX MX2007003624A patent/MX2007003624A/es active IP Right Grant
- 2005-09-22 CN CN2005800403891A patent/CN101065398B/zh active Active
- 2005-09-22 DK DK05794474.6T patent/DK1803732T3/da active
- 2005-09-22 JP JP2007532752A patent/JP4755649B2/ja active Active
- 2005-09-22 AT AT05794474T patent/ATE546462T1/de active
- 2005-09-22 CA CA2797769A patent/CA2797769C/en active Active
- 2005-09-22 KR KR1020107001135A patent/KR101035283B1/ko active IP Right Grant
- 2005-09-22 EP EP05794474A patent/EP1803732B1/en active Active
- 2005-09-22 RU RU2007115411/04A patent/RU2361877C2/ru active
- 2005-09-22 AU AU2005287757A patent/AU2005287757B2/en not_active Ceased
- 2005-09-22 ES ES10189769.2T patent/ES2445707T3/es active Active
- 2005-09-22 KR KR1020077008682A patent/KR101054332B1/ko active IP Right Grant
- 2005-09-22 DK DK10189769.2T patent/DK2371847T3/da active
- 2005-09-22 CN CN2010100038161A patent/CN101935345B/zh active Active
- 2005-09-22 EP EP10189769.2A patent/EP2371847B1/en active Active
- 2005-09-22 CA CA2581110A patent/CA2581110C/en active Active
- 2005-09-22 BR BRPI0515893A patent/BRPI0515893B8/pt active IP Right Grant
- 2005-09-22 WO PCT/CU2005/000008 patent/WO2006032216A2/es active Application Filing
- 2005-09-22 ES ES05794474T patent/ES2386498T3/es active Active
- 2005-09-22 US US11/663,603 patent/US8383771B2/en active Active
-
2007
- 2007-04-10 ZA ZA200702938A patent/ZA200702938B/xx unknown
-
2009
- 2009-12-28 AR ARP090105137A patent/AR074924A2/es active IP Right Grant
- 2009-12-30 US US12/649,687 patent/US8324164B2/en active Active
-
2010
- 2010-09-06 AU AU2010219312A patent/AU2010219312B2/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000072023A2 (en) | 1999-05-21 | 2000-11-30 | Semmelweis University Of Medicine | Diagnosis and treatment of atherosclerosis and coronary heart disease |
WO2002057795A2 (en) | 2001-01-19 | 2002-07-25 | Cambridge Scientific, Inc. | Methods of diagnosis and treatment of osteoporosis |
Non-Patent Citations (2)
Title |
---|
BRESHINAN, B.: "Treatment of rheumatoid arthritis with recombinant human anti-interleukin-1 antagonist", ARTHRITIS REURN., vol. 41, 1998, pages 2196 - 2204 |
QUINTANA ET AL., J IMMUNOL, vol. 171, 2003, pages 3533 - 3541 |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10925942B2 (en) | 2007-01-30 | 2021-02-23 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
US11045532B2 (en) | 2007-01-30 | 2021-06-29 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
CN103755789A (zh) * | 2007-01-30 | 2014-04-30 | 埃皮瓦克斯公司 | 调节性t细胞表位、组合物及其用途 |
CN103755789B (zh) * | 2007-01-30 | 2016-12-07 | 埃皮瓦克斯公司 | 调节性t细胞表位、组合物及其用途 |
CN107011431A (zh) * | 2007-01-30 | 2017-08-04 | 埃皮瓦克斯公司 | 调节性t细胞表位、组合物及其用途 |
US10213496B2 (en) | 2007-01-30 | 2019-02-26 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
CN107011431B (zh) * | 2007-01-30 | 2020-11-06 | 埃皮瓦克斯公司 | 调节性t细胞表位、组合物及其用途 |
US11045528B2 (en) | 2007-01-30 | 2021-06-29 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
US11045530B2 (en) | 2007-01-30 | 2021-06-29 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
CN101687912B (zh) * | 2007-01-30 | 2014-01-22 | 埃皮瓦克斯公司 | 调节性t细胞表位、组合物及其用途 |
US10751397B2 (en) | 2007-01-30 | 2020-08-25 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
US10925939B2 (en) | 2007-01-30 | 2021-02-23 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
US10925940B2 (en) | 2007-01-30 | 2021-02-23 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
US10925941B2 (en) | 2007-01-30 | 2021-02-23 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
US10980867B2 (en) | 2007-01-30 | 2021-04-20 | Epivax Inc. | Regulatory T cell epitopes, compositions and uses thereof |
US11045531B2 (en) | 2007-01-30 | 2021-06-29 | Epivax Inc. | Regulatory T cell epitopes, compositions and uses thereof |
US11045529B2 (en) | 2007-01-30 | 2021-06-29 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
CN112279911A (zh) * | 2007-01-30 | 2021-01-29 | 埃皮瓦克斯公司 | 调节性t细胞表位、组合物及其用途 |
WO2010075824A1 (es) | 2008-12-29 | 2010-07-08 | Centro De Ingeniería Genética Y Biotecnología | Uso de peptido tipo apl para el tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i |
WO2019129315A1 (es) | 2017-12-29 | 2019-07-04 | Centro De Ingenieria Genetica Y Biotecnologia | Composición farmaceutica que comprende un peptido tipo apl |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2445707T3 (es) | Péptidos y derivados tipo APL de Hsp60 y composiciones farmacéuticas | |
TWI750122B (zh) | 用於贅瘤疫苗之調配物及其製備方法 | |
KR20160096643A (ko) | 신생물 백신을 위한 제형 | |
CZ122697A3 (en) | Preparations and methods of treating disseminated sclerosis | |
JPH10509136A (ja) | ポリペプチドと自己−免疫疾患の治療および予防におけるその使用 | |
Offner et al. | Response of rat encephalitogenic T lymphocyte lines to synthetic peptides of myelin basic protein | |
CA2418445A1 (en) | Stress proteins and peptides and methods of use thereof | |
US20060270833A1 (en) | Peptide complex | |
US10821164B2 (en) | Peptides for inducing Chagas disease responses | |
JP2006508901A (ja) | T細胞非結合性ペプチド及びその用途 | |
Shen et al. | Characterization of the dominant autoreactive T-cell epitope in spontaneous autoimmune haemolytic anaemia of the NZB mouse | |
WO2022179093A1 (zh) | 用于治疗自身免疫性疾病的多肽 | |
WO2023180547A1 (en) | Mhc ib-mediated islet-antigen-specific immunosuppression as a novel treatment for type 1 diabetes | |
PT1319020E (pt) | Variantes do importante alergénio par j 2 de parietaria judaica | |
del Carmen Domínguez et al. | Suppression of the pathogenic responses in an animal model of adjuvant-induced arthritis by a peptide corresponding to a novel epitope from heat-shock protein 60 | |
JP2019511215A (ja) | ヒトミオシンペプチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007532752 Country of ref document: JP Ref document number: 2581110 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/003624 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2665/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005794474 Country of ref document: EP Ref document number: 1020077008682 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005287757 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007115411 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2005287757 Country of ref document: AU Date of ref document: 20050922 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580040389.1 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005794474 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11663603 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0515893 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020107001135 Country of ref document: KR |
|
ENPC | Correction to former announcement of entry into national phase, pct application did not enter into the national phase |
Ref country code: BR Free format text: ANULADA A PUBLICACAO CODIGO 1.3.1 NA RPI NO 2504 DE 02/01/2019 POR TER SIDO INDEVIDA. |